This inventor holds 1 USPTO granted patent. Top assignees: Bloomage Biotechnology Corporation Limited, Shandong University. Active years: 2024.
Company Filing History:

Years Active: 2024
Title: The Innovations of Ranran Du
Introduction
Ranran Du is a prominent inventor based in Jinan, China. He has made significant contributions to the field of biotechnology, particularly in the development of heparin skeleton synthase. His work has implications for various medical applications, showcasing his innovative spirit and dedication to advancing science.
Latest Patents
Ranran Du holds a patent for "Heparin skeleton synthase and its mutants and application." This invention describes a heparin skeleton synthase that originates from a specific amino acid sequence, as shown in SEQ ID NO.2, and a nucleotide sequence of the coding gene, as shown in SEQ ID NO.1. The recombinant expression level of this synthase is 6.8 times that of the existing heparin skeleton synthase KfiA from K5. Additionally, the total enzyme activity per fermentation liquor is 5.22 times that of KfiA. The mutants of the heparin skeleton synthase, obtained through site-directed mutagenesis at specific sites in the amino acid sequence, exhibit high expression levels.
Career Highlights
Throughout his career, Ranran Du has worked with notable organizations, including Bloomage Biotechnology Corporation Limited and Shandong University. His experience in these institutions has allowed him to collaborate with other experts in the field and further his research endeavors.
Collaborations
Ranran Du has collaborated with esteemed colleagues such as Jianqun Deng and Juzheng Sheng. These partnerships have contributed to the advancement of his research and the successful development of his patented innovations.
Conclusion
Ranran Du's contributions to biotechnology, particularly through his patent on heparin skeleton synthase, highlight his innovative capabilities and commitment to scientific progress. His work continues to influence the field and pave the way for future advancements.